Trial Profile
An Open Label Dose Escalation Clinical Trial to Evaluate the Safety and the Tolerability of GS010 (rAAV2/2-ND4) in Patients With Leber Hereditary Optic Neuropathy Due to Mutations in the Mitochondrial NADH Dehydrogenase 4 Gene
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 16 Mar 2023
Price :
$35
*
At a glance
- Drugs Lenadogene nolparvovec (Primary)
- Indications Leber's hereditary optic atrophy
- Focus Adverse reactions; First in man
- Acronyms REVEAL Study
- Sponsors GenSight Biologics
- 09 Mar 2023 According to a GenSight Biologics media release, company announced publication of a peer-reviewed article in American Journal of Ophthalmology on pooled safety analysis of lenadogene nolparvovec from five clinical studies (REVEAL, RESCUE, REVERSE, RESTORE and REFLECT).
- 24 Jan 2022 According to a GenSight Biologics media release, the review of the European Marketing Authorisation Application for LUMEVOQ is ongoing, with the decision from the CHMP expected in Q4 2022.
- 29 Jul 2021 According to a GenSight Biologics media release, Following a delay in manufacturing validation batches of LUMEVOQ as a consequence of the US Defense Production Act (DPA), The EU marketing authorization is expected in H1 2022.